361 Capital’s Pfizer PFE Stock Holding History

361 Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-65,869	Closed	-$2.22M	–	371
2018 Q1	$2.22M	Buy	+65,869	New	+$2.26M	0.55%	31

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

361 Capital's PFE Position: Q2 2018 in Review

361 Capital sold out of Pfizer (PFE) in Q2 2018, closing a stake of 65,869 shares — an estimated $2.22M sold.

361 Capital first reported a position in PFE in Q1 2018 and held it in 1 quarter. The position peaked at $2.22M in Q1 2018. 2,204 funds tracked by Wall St. Rank hold PFE as of Q2 2018.

361 Capital reported no remaining Pfizer position as of Q2 2018 after selling out during the quarter.
361 Capital sold 65,869 Pfizer shares in Q2 2018, an estimated $2.22M.
361 Capital first reported a position in Pfizer in Q1 2018 and held it in 1 quarter.
361 Capital's Pfizer position peaked at $2.22M in Q1 2018.
2,204 funds tracked by Wall St. Rank held Pfizer as of Q2 2018.

Based on 361 Capital's 13F filing for Q2 2018, filed 14 Aug 2018.